Sanofi, GSK Say Covid Shot Is Effective Against Omicron (1)

Sanofi and GSK Plc said their potential Covid-19 vaccine, which is based on the beta strain of the virus, is effective in adults, particularly against the omicron variant.

The duo said a trial showed the shot has a near 65% efficacy rate against symptomatic infection in adults overall and was 72% effective in adults when tested against the omicron variant. It had even higher effectiveness in adults previously infected with Covid-19, with a 93.2% efficacy rate against omicron.

Earlier this month, the two companies reported positive data from two trials on their “next-generation” Covid-19 booster shot which is modeled on ...